Science & Enterprise subscription

Follow us on Twitter

  • Results of a pilot test show a smartphone app makes a common test for the pregnancy complication preeclampsia simpl… https://t.co/AN5bKtBQrG
    about 6 hours ago
  • New post on Science and Enterprise: App Automates, Simplifies Test for Preeclampsia https://t.co/lSyEXavP4X #Science #Business
    about 6 hours ago
  • Computer scientists in the U.K. and France created techniques for adding a refined sense of touch to highly sensiti… https://t.co/ilWVpMNqZb
    about 13 hours ago
  • New post on Science and Enterprise: Touch Senses Added to Synthetic Skin, Robot Arm https://t.co/KMpa31SgZP #Science #Business
    about 13 hours ago
  • The NBI is in decline since reaching its peak for the year in the spring, erasing all of the gains for the year at… https://t.co/PF5ud7Vlk3
    about 2 days ago

Please share Science & Enterprise

U.K. Medical Tech Company Acquires Wound Care Developer

Human keratinocyte cells (USDA.gov)

Human keratinocyte cells (USDA.gov)

Smith & Nephew, a medical technology company in London, is purchasing Healthpoint Biotherapeutics, a developer of wound treatments in Fort Worth, Texas. In the transaction, Smith & Nephew will acquire all Healthpoint assets for $782 million in cash, with the deal expected to close next month.

Olivier Bohuon, Smith & Nephew’s CEO, says the acquisition “reinforces our advanced wound management division by giving us a strong position in the fast growing area of bioactive wound care treatment.” In addition to wound care, Smith & Nephew offers products in orthopedic reconstruction, sports medicine, and trauma therapies.

Healthpoint develops a range of biologic products for treating burns and skin ulcers, including treatments for removing dead tissue in wounds, artificial skin substitutes, and a bioactive cell therapy to treat venous and diabetic leg ulcers that can be slow to heal. The company’s lead pipeline product is HP802-247, a spray-on compound made from skin cells known as keratinocytes (pictured right) and fibroblasts suspended in a mixture of various proteins to help with blood clotting. In September, Healthpoint started a phase 3 clinical trial of HP802-247, after reporting successful phase 2 trials in August.

Smith & Nephew has some 11,000 employees worldwide and a presence in more than 90 countries. Annual sales in 2011 were nearly $4.3 billion. Healthpoint has 460 employees with revenues of $151 million in 2011 and $190 million expected this year. Smith & Nephew says it plans to keep Healthpoint’s operations in Fort Worth, and slowly integrate the company’s operations into Smith & Nephew’s wound care division to minimize disruption.

Travis Baugh, president of Healthpoint says of the acquisition, “It will enable us to accelerate many of the initiatives we wanted to pursue and will provide development and promotional opportunities to our employees that would not have been available to them had we stayed an independent company.”

Read more:

Hat tip: MedCity News

*     *     *

Please share Science & Enterprise ...
error

Comments are closed.